By Michael Dabaie

 

AstraZeneca said results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi significantly improved overall survival in liver cancer.

The trial met the primary objective of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks versus sorafenib for patients with unresectable hepatocellular carcinoma, or HCC, the company said. Imfinzi monotherapy met the overall survival endpoint of non-inferiority versus sorafenib, AstraZeneca said.

Imfinzi and tremelimumab were granted orphan drug designations in the U.S. for the treatment of HCC in 2020. Tremelimumab was also granted orphan designation in the European Union in HCC in 2020.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

October 15, 2021 07:50 ET (11:50 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Nov 2021 a Dic 2021 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Dic 2020 a Dic 2021 Clicca qui per i Grafici di Astrazeneca